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Abstract
Purpose of review An increasing body of evidence indicates
that bio-energetic metabolism of activated Tcells is a potential
target to control the autoimmune response in type 1 diabetes
(T1D).
Recent findings T-cell activation and proliferation is linked to
the cell capacity to provide sufficient energy and biosynthesis
molecules to support T-cell growth and division. This makes T
cells susceptible to metabolic inhibition for the control of the
T-cell response. There is a wide therapeutic arsenal of meta-
bolic inhibitors, including novel classes of drugs that have
become recently available.
Summary With the current knowledge and availability of met-
abolic inhibitors, we are now in the position to design a met-
abolic inhibition strategy to determine whether targeting of
autoreactive T cells is an effective strategy to control the pro-
cess of β-cell destruction in T1D.
Keywords Type 1 diabetes . Tcells . Immune-metabolism .
Autoimmunity
Introduction
Autoreactive T cells have a pivotal pathogenic role in the
autoimmune process of β-cell destruction. Consequently,
autoreactive T cells are an ideal target for immunotherapy
strategies aiming to prevent or delay the onset of the disease.
In patients with type 1 diabetes (T1D), autoreactive T cells are
largely refractory to standard immunosuppressive [1] and im-
munomodulatory strategies [2–4], and the identification and
characterization of novel target pathways to control the T-cell
response to β cells is still a strong need. In recent years, there
was an ever-growing appreciation of how every aspect of the
T-cell response is tightly linked to bio-energetic metabolism
[5]. Resting T cells need basal energy production and biosyn-
thesis to support house-keeping functions and homeostasis.
On the other hand, activation, clonal expansion, and acquisi-
tion of effector functions of T cells are energetic and biosyn-
thetic demanding processes. Immediately upon activation, T
cells strongly upregulate the anabolic process of glycolysis
even in the presence of oxygen (Warburg effect). Later, also
oxidative phosphorylation fueled by amino acids is upregulat-
ed to sustain proliferation. The extraordinary energetic and
biosynthetic needs during expansion also make T cells vulner-
able to apoptosis and unresponsive if these needs are not ful-
filled. This opened a new perspective on the potential to con-
trol the T-cell response by manipulating metabolism with
drugs [6]. A consistent number of publications indicate that
metabolic inhibition is an effective strategy to control the T-
cell response in preclinical models of autoimmunity and trans-
plantation. In this paper, we will review recent literature on T-
cell metabolism to understand whether we can envisage a
translation of this novel approach to control β-cell autoimmu-
nity. An ideal immunotherapy for T1D has to be nontoxic,
limited in time, selective on autoreactive T cells, and provide
long-term effect in the control of β-cell autoimmunity. We
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will attempt to design a potential strategy of metabolic inhibi-
tion that satisfy these needs, considering the current knowl-
edge on T-cell metabolism and the current availability of drugs
targeting metabolism.
Brief Overview of Metabolic Pathways
Cells regulate the activity of metabolism to couple generation
of energy and biosynthesis intermediates for survival and pro-
liferation [7]. Glycolysis and oxidative phosphorylation
(OXPHOS) are the two processes by which cells produce
chemical energy in the form of ATP. Glucose is one of the
substrates from which cells produce energy, and glycolysis
begins with the uptake of extracellular glucose. Glycolysis
converts glucose into pyruvate via a series of intermediate
metabolites that can enter the pentose phosphate pathway, thus
contributing to biosynthesis for cell growth. In the mitochon-
dria, pyruvate can be converted into acetyl-CoA, which enters
the tricarboxylic acid (TCA) cycle. Alternatively, pyruvate
can be converted in the cytoplasm into lactate, which is ex-
creted from the cell. In addition to energy and biosynthesis
intermediates, glycolysis also allows the reduction of NAD+
to NADH, thus contributing to the cell redox balance. Lipids
enter the fatty acid oxidation (FAO) process providing inter-
mediates that enter the TCA cycle. Also, amino acids such as
glutamine can bemetabolized to produce intermediates for the
TCA cycle. Glutamine is converted into glutamate by gluta-
minase. Glutamate enters the mitochondria through the mito-
chondrial glutamate transporter and is used in the TCA cycle.
Oxidation of substrates in the TCA cycle produces the coen-
zymes NADH and FADH2 and gives electrons to the electron-
transport chain to sustain OXPHOS. The TCA cycle also pro-
duces intermediates for biosynthetic pathways, such as citrate,
which is used for fatty acids synthesis. ATP production by
aerobic glycolysis is 10 times less efficient than by
OXPHOS. The T-cell decision to use glycolysis or
OXPHOS is dictated by the state of activation to find the
optimal balance for ATP production, biosynthetic substrates,
and redox condition.
Metabolism of Quiescent and Activated T Cells
Quiescent, non-proliferating T cells have low energetic and
biosynthetic demand and use glucose, fatty acids, and amino
acids to fuel ATP generation by the catabolic process of
OXPHOS. Survival of naïve T cells depends on interleukin-
7 signaling [8], which acts as a master regulator of metabolism
by promoting extracellular glucose uptake via GLUT-1, and
by transcriptional control of the glycolytic enzyme exokinase
II gene. In the absence of IL-7, naïve T cells reduce metabolic
activity and rapidly undergo atrophy. Resting memory T cells
have a greater mitochondrial mass and an increased spared
respiratory capacity (SRC) than that of naïve T cells [9].
This is closely related to the capacity of memory T cells to
provide immediate metabolic activation for rapid recall re-
sponse. Memory T cells synthetize lipids that serve to fuel
FAO in the mitochondria starting either from extracellular
glucose or glycerol. Glycerol is acquired from the extracellu-
lar environment through the IL-7-dependent expression of the
glycerol channel aquaporin 9 (AQP9) [10••]. Glycerol is sub-
sequently used for fatty acid esterification and triglyceride
(TAG) synthesis and storage, which appear to be a critical
process for long-term memory T-cell survival.
Upon antigen recognition, signals from the TCR, with
proper co-stimulation and cytokine signals, lead to T-cell pro-
liferation and activation. The rate of cell growth and division
of activated T cells during clonal expansion is unique in the
body and requires an extraordinary amount of energy and
substrates to build the “blocks” for growth. One of the most
striking changes to affect T cells upon antigenic stimulation is
the metabolic reprogramming (Fig. 1). T cells significantly
enhance glucose uptake, through increased expression of
GLUT1 [11]. A parallel production of lactate indicates that
pyruvate has been reduced rather than undergooxidation in
the TCA cycle. The initial burst of glycolysis appears to be
necessary for the production of biosynthetic precursor mole-
cules. Catabolic OXPHOS is actively suppressed as the pro-
duction of ATP from mitochondria would increase the
Figure 1 T-cell metabolism and inhibitors. Upon antigen recognition,
activated T cells activate glycolysis and subsequently mitochondrial
oxidative metabolism to produce energy and biosynthesis intermediates
for cell growth and proliferation. The GLUT1 inhibitor WZB117, the
ETC inhibitor metformin, and the glutaminase inhibitor CB839 are
potential candidate molecules to induce a metabolic blockade. GLUT1
glucose transporter 1, TCA tricarboxylic acids
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ATP:ADP ratio reducing the glycolytic rate. The metabolism
of T cells early after antigen encounter largely relies on gly-
colysis even in the presence of oxygen to support mitochon-
drial oxidations. This is reminiscent of the Warburg effect,
which is a hallmark of cancer cell metabolism and was exten-
sively studied as a target to affect cell growth and replication.
After the acute phase of activation characterized by glycolysis,
oxidative mitochondrial processes increase in chronically ac-
tivated T cells [10••]. Pyruvate is oxidized in the TCA cycle
and pyruvate dehydrogenase is down-regulated. In addition to
pyruvate, critical substrates used by activated T cells are glu-
tamine and fatty acids [12•]. With respect to the signaling
pathways involved in metabolic reprogramming, TCR activa-
tion along with CD28 co-stimulation triggers the activity of
phosphatidylinositol 3′-kinase (PI3K) and downstream activa-
tion of the serine-threonine kinase Akt. Akt promotes the lo-
calization of GLUT1 to the plasma membrane to facilitate
glucose uptake, and increases the activity of the glycolytic
enzymes hexokinase and phosphofructokinase [13]. In addi-
tion, Akt promotes the mammalian target of rapamycin
(mTOR) activity by relieving inhibition of RhebGTP by the
TSC1-TSC2 complex [14]. mTOR activation modulates the
rate of protein synthesis by regulating the process of cap-
dependent translation and by increasing the surface expression
of amino acid transporters [15]. The mTOR pathway leads to
the expression of downstream transcriptional regulators, in-
cluding c-Myc, and the hypoxia inducible factor 1α, (HIF-
1α). Activation of c-Myc is associated with the expression
of enzymes that promote aerobic glycolysis, and upregulation
of glutaminolysis to enhance production of amino acids,
lipids, and nucleic acids necessary for cell growth [16]. HIF-
1α is a transcription factor that responds to oxygen levels,
acting as an important promoter of glucose uptake and glycol-
ysis in many cell types, including T cells [17].
Although much of the attention on metabolic changes in T
cells upon activation has focused on the early upregulation of
glycolysis, recent findings have revealed the role of oxidative
metabolism in the mitochondria. Mitochondrial OXPHOS is
activated later than glycolysis and is active in chronically ac-
tivated T cells, such as alloreactive T cells mediating graft vs
host disease [18]. It was proposed that after the initial phase of
activation, T cells undergo metabolic stress, perhaps due to
limitation in nutrients, cytokines, and antigenic stimulation
switching from glycolysis to other catabolic processes, like
fatty acid oxidation [19]. This switch is a key step to the
survival of proliferating clones to develop long-lived memory
cells during the contraction phase of the T-cell response. In
addition to ATP production, mitochondrial oxidation can in-
fluence the T-cell proliferation rate though production of reac-
tive oxygen species (ROS) [20•]. The lymphocyte expansion
molecule (LEM) controls the levels of OXPHOS complexes
and regulates the production of pro-proliferative ROS in the
mitochondria of activated T cells.
Controlling the T-Cell Response
Through Metabolism
The rapid and extensive clonal expansion capacity of Tcells is
unique among cells in the body. The extraordinary energetic
and biosynthetic effort needed to support these processes
makes proliferating T cells particularly amenable to metabolic
manipulation. Metabolic manipulation not only influences
proliferation but also differentiation into different T-cell sub-
sets, the generation of memory T cells, and the capacity to
respond to recall antigen in the long term. Several studies have
shown that molecules interfering with T-cell metabolism in-
fluence the final outcome of the T-cell response. The mTOR
inhibitor rapamycin, which is widely used as an anti-
proliferative immunosuppressive drug, was shown to promote
the generation of memory T cells in the CD8+ T-cell subset
[21]. One possibility is that mTOR blocking induces a switch
to catabolic metabolism in proliferating naïve T cells. The
anti-diabetes drug metformin, which act as activator of
AMPK and inhibitor of the electron transport chain in the
mitochondria, also enhances CD8 T-cell memory generation
[19]. It is likely that the effect of both rapamycin and metfor-
min on memory T-cell generation is a consequence of a met-
abolic manipulation. Indeed, specific induction of FAO results
in an increased generation of memory T cells and indicates
that promoting catabolic pathways is crucial to the develop-
ment of long-lived memory cells. A population of memory T
cells with stem cell-like properties has been recently identified
and characterized in mice, non-human primates, and humans,
and named stem cell memory T cells [22]. The existence of
autoreactive Tscm precursors has been hypothesized also in
type 1 diabetes (T1D) [23]. Tscm can be generated by activa-
tion of naïve Tcells in the presence of the glycogen synthetase
kinase beta (GSK3b) inhibitor TWS119 [24]. In addition,
Tscm can be generated by culturing naïve T cells in the pres-
ence of IL-7 and IL-15, which are modulators of T-cell glyco-
lytic and mitochondrial metabolism [25]. The availability of
nutrients also impacts T-cell activation and proliferation.
Glucose is a fundamental nutrient for CD8+ T-cell cytolytic
activity and cytokine production. Consequently, these func-
tions are impaired in glucose-limiting conditions, such as in
the tumor microenvironment. Low concentration of extracel-
lular glucose is a hallmark of the milieu of tumors with high
glycolytic rate. CD8+ T cells isolated from these tumors have
impaired interferon-γ production and reduced mTOR activa-
tion compared with that of T cells from tumors with basal
levels of glycolysis [26•]. T-cell survival and function also
depend on availability of amino acids. In vitro T-cell prolifer-
ation and cytokine production is severely impaired by deple-
tion of glutamine from the culture medium and it is likely that
competition for glutamine can influence the T-cell response
[27••]. The role of other amino acids is currently under inves-
tigation. Deficiency in the leucine transported Slc7a5 (LAT1)
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was shown to prevent proliferation and effector functions of
both CD4+ and CD8+ Tcells [28]. The mechanism involves a
defective activation of mTOR and impairment of the uptake of
glucose and glutamine to fuel metabolic processes.
Also by-products generated during metabolic processes
can affect the T-cell response. Lactate is produced during gly-
colysis and then excreted in the extracellular milieu. Lactate
promotes the differentiation of Th17 cells and inhibits the
cytolytic activity of CD8+ T cells [29]. Indoleamine-2,3-
dioxigenase mediates tryptophan catabolism and produces
kynurenine, which induces the generation of regulatory Tcells
and acts as a potent suppressor of effector T-cell proliferation
[30]. These data show how metabolic activity is involved in
the T-cell fate during an immune-response, and open the pos-
sibility to control the T-cell response by targeting metabolic
processes with specific drugs.
Drugs and Molecules Targeting Metabolism
The possibility to target metabolic pathways in T cells is rel-
atively recent; however, this therapeutic option has been ex-
tensively explored to treat cancer, and several drugs and mol-
ecules have been developed and become available (Table 1).
Two important inhibitors of glycolysis are 2-deoxy-D-glucose
(2DG) and 2-fluoro-deoxy-D-glucose (2FDG) [31]. The struc-
ture of 2DG is identical to that of D-glucose, except that the
C-2 hydroxyl group is replaced with hydrogen. As for D-glu-
cose, 2DG is taken up by cells through trough GLUTs
transporters. In the cell, 2DG is phosphorylated by hexokinase
(the first enzyme of the glycolytic pathway) to form 2DG-6-
phosphate, which cannot be subsequently processed through
the glycolytic pathway. 2DG-6-phosphate accumulates in the
cel l and competes with glucose-6-phosphate for
phosphoglucose isomerase (PGI) in the subsequent reversible
glycolytic step. Thus, the primary way by which 2DG blocks
glycolysis is by competitive inhibition of PGI. 2FDG is more
potent than 2DG in inhibiting glycolysis. This correlates with
the closer structural similarity of 2FDG to glucose than 2DG.
This increases the binding of 2FDG to the catalytic subunit of
hexokinase and consequently an increased production of
2FDG-6-phosphate and enhanced inhibition of PGI. Both
2DG and 2FDG are highly toxic compounds and their mech-
anism of inhibition of the glycolytic enzymes causes inhibi-
tion of glucose metabolism virtually in every cell in the body.
A novel class of small molecules that inhibit glycolysis by
blocking glucose uptake through the GLUT1 transporter has
recently been developed. The advantage of these compounds
is that GLUT1 is used for glucose uptake predominantly by
neurons, activated T cells, and certain types of cancer cells,
and they should not interfere with the glycolytic pathway of
other cells using different glucose transporters. STF-31 is a
GLUT1 inhibitor, which showed a selective toxicity of renal
cancer cells expressing GLUT1 and using glycolysis for ATP
production [32]. Normal kidney cells are not strictly depen-
dent on glycolysis, use GLUT2 for glucose uptake, and are
therefore insensitive to STF-31 toxicity. When used in a
mouse model, STF-31 efficiently blocked tumor growth
Table 1 Molecules targeting
metabolic pathways Molecule Target Disease Clinical (C), Preclinical (P) Ref





Allograft rejection P [42•]
Bz-423 F1F0-ATPase GVHD P [18]
2DG Hexokinase Cancer C [55]
T1D P [41••]
Lupus P [39••]
Allograft rejection P [42 •]
WZB117 GLUT1 Cancer P [33]
STF31 GLUT1 Cancer P [32]
DON Glutaminase Cancer C [56]
Allograft rejection P [42•]
BPTES Glutaminase Cancer C [57]
CB839 Glutaminase Cancer C [37]
2DG 2-deoxy-D-glucose, BPTES Bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl) ethyl sulfide,DON 6-diazo-5-
oxo-l-norleucine, EAE experimental autoimmune encephalomyelitis, ETC electron transport chain, GLUT1 glu-
cose transporter 1, GVHD graft versus host disease, T2D type 2 diabetes
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without significant toxic effect on other organs. Similarly,
WZB117 is a small molecule competitively inhibiting
GLUT1-mediated glucose transport [33]. WZB117 was
shown to kill lung and breast cancer cells without affecting
normal cells. As for STF-31, in vivo treatment of animal
models with WZB117 inhibited tumors without causing sig-
nificant adverse events in treated animals.
Mitochondrial metabolism seems to be important for
chronically activated T cells. Targeting of mitochondrial me-
tabolism can be achieved by inhibiting the mitochondrial
F1F0-ATPase with the benzodiazepine Bz-423 [18]. In a
mouse model of bonemarrow transplantation and graft vs host
disease (GVHD), it was shown that while expanding bone
marrow cell relies on glycolysis, T cells proliferating in re-
sponse to allo-antigens during GVHD increased both aerobic
glycolysis and OXPHOS. In the model, the use of the F1F0-
ATPase inhibitor Bz-423 induced selective apoptosis in Tcells
arresting established GVDH without affecting hematopoietic
and immune reconstitution. The mechanism by which apopto-
sis is triggered in activated alloreactive Tcells was the increase
of superoxide. Even though these findings challenged the cur-
rent view that activated T cells are dependent from aerobic
glycolysis, they also indicate that manipulation of the redox
status and mitochondrial activity can be target pathways in
novel therapeutic options for immune disorders. Metformin
belongs to the biguanide class of drugs and is widely used
for the treatment of type 2 diabetes (T2D) [34]. Metformin
affects metabolism as inhibitor of the mitochondrial respirato-
ry chain (complex I) and by activating the AMP-activated
protein kinase (AMPK). AMPK is an energetic cell sensor
that monitors the AMP/ATP ratio and induces the metabolic
reaction to energetic stress. This includes the inhibition of
mTOR through the phosphorylation of the tumor suppressor
TSC2, which inactivates Rheb and dampens mTOR activity.
In addition, AMPK also phosphorylates Raptor, which binds
to and regulate the activity of mTOR. AMPK dampens ana-
bolic metabolism and increases FAO.
Glutaminase, the enzyme that converts glutamine into glu-
tamate, is the target of several drugs developed to inhibit the
process of glutamine oxidation in the TCA. Several drugs
acting on glutaminolysis have been developed in cancer re-
search and showed inhibition of tumor growth in vitro and
in vivo [35]. Some of these drugs can find an application also
in the control of the T-cell response. The glutamine analog 6-
diazo-5-oxo-l-norleucine (DON) inhibits glutaminase, but al-
so a range of glutamine-dependent enzymes (such as gluta-
mine fructose-6-phosphate amidotransferase), as well as other
glutamine-dependent reactions, making its biological activity
nonspecific. Bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-
yl)ethyl sulfide (BPTES) is an allosteric inhibitor of glutamin-
ase that showed minimal off-target effects [36]. Other GLS
inhibitors have been developed, including the BPTES-like
drug candidate CB-839 and compound 968, which are
currently being tested in clinical trials to determine efficacy,
toxicity, and side effects in humans [37]. At the moment, CB-
839 and compound 968 are the most advanced and promising
drugs available to specifically inhibit glutamine metabolism.
An alternative option to inhibit glutamine metabolism with a
well-known drug would be rapamycin, which is a widely used
immunosuppressive drug. mTORC1 activation has been cor-
related with increased nutrient uptake and metabolism, but no
connection to glutaminolysis has been initially reported.
However, a recent paper showed that mTORC1 promotes glu-
tamine anaplerosis by activating glutamate dehydrogenase
(GDH) [38]. This regulation requires transcriptional repres-
sion of SIRT4, the mitochondrial-localized sirtuin that inhibits
GDH. Considering the role of mTORC1 activation in induc-
ing glucose metabolism, rapamycin can be considered to be a
multi-target metabolic inhibitor, in addition to a wide range of
immunological effects. Metabolic inhibitors have been tested
in animal models of autoimmunity and transplantation.
Systemic lupus erythematosus (SLE) is supported by chronic
activation of CD4+ T cells supported by both glycolysis and
mitochondr ia l metabolism. In vivo treatment of
B6.Sle1.Sle2.Sle3 (TC) mice with a combination of metfor-
min and 2-deoxy-D-glucose (2DG) led to normalization of T-
cell metabolism and reversed disease biomarkers [39••].
Moreover, T cells isolated from patients with SLE also exhib-
ited increased glycolysis and mitochondrial metabolism, and
in vitro treatment with metformin slightly reduced IFN-γ pro-
duction. A study conducted in a mouse model of experimental
autoimmune encephalomyelitis (EAE) showed that treatment
of mice with metformin reduced pathogenic Th17 cell while
increasing the percentage of Foxp3+ regulatory T cells secret-
ing TGF-β and IL-10 [40•]. Metformin treatment attenuates
clinical signs of EAE and the mechanism of action involved
the suppression of the mTOR pathway and its downstream
target HIF-1α. Immune therapy with metabolic blockade has
been tested in the non-obese diabetic (NOD) mouse model
[41••]. The authors studied diabetogenic CD8+ T cells that
recognize a peptide from the diabetes antigen IGRP (NRP-
V7-reactive) in pre-diabetic NOD mice and found that they
have features of memory Tcells, including an increased use of
glycolysis and reduced use of oxidative phosphorylation.
Blocking glucose metabolismwith 2-DG resulted in a reduced
frequency of these cells, a reduced islet infiltrate, and in im-
proved β-cell granularity. Metabolic inhibition can be an ef-
fective strategy to prevent allograft rejection. In a model of
skin or heart transplantation from Balbc into C57BL6 mice, a
triple inhibition of glycolysis with 2DG,mitochondrial metab-
olism with metformin and glutaminolysis with the glutamin-
ase inhibitor 6-diazo-5-oxo-L-norleucine (DON) was proven
to be effective in preventing allograft rejection [42•].
Although these findings are still preliminary, metabolic ma-
nipulation is becoming a promising therapeutic venue for im-
mune disorders, including autoimmunity.
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Targeting T-Cell Metabolism in Type 1 Diabetes
With the best of our current knowledge and the availability of
novel classes of metabolic inhibitors, how would we design a
metabolic inhibition immunotherapy for T1D (Fig. 2)? Our
primary goal is to permanently and selectively unarm
autoreactive T cells with a short-term treatment. The expecta-
tion is that metabolic blockade during antigen specific T-cell
activation may induce anergy and apoptosis in activated
clones, resulting in a long-term effect on the autoimmune T-
cell repertoire. T cells are particularly susceptible to metabolic
inhibition right after activation and during the clonal expan-
sion phase. Unfortunately, in the natural history of the disease
it is not possible to determine a time window in which quies-
cent autoreactive Tcells get activated by antigens [43–45]. An
ideal model is islet transplantation in patients with T1D. In the
model, quiescent autoreactive T cells (including memory
clones) are re-exposed to β-cell antigens (islet graft) [46]
and metabolic inhibition could be envisaged as an induction
therapy in this clinical setting. With respect to the natural
history of T1D, however, one possibility would be to associate
metabolic blockade to antigen specific vaccination with β-cell
associated antigens [47] such as GAD65 [48]. The duration of
the treatment is an important issue. While metabolic
reprogramming is rapid and occurs within hours from antigen
recognition, the time sequence for the initial glycolytic burst
and the later activation of oxidative phosphorylation last for
several days. A metabolic blockade of 2 weeks should be able
to cover all the metabolic events of acute and chronic T-cell
activation. With respect to the metabolic inhibitors to be used,
we envisage a treatment for blocking all the three main path-
ways: glycolysis, OXPHOS, and glutaminolysis. With respect
to glycolysis inhibitors, the best candidate is the specific
GLUT1 inhibitor WZB117. Inhibition of GLUT1 has the im-
portant advantage of targeting cells that preferentially use
GLUT1 for glucose uptake. This includes activated T cells
and neurons [49]. Neurons also express GLUT3 that mediates
glucose uptake in conditions of low extracellular glucose such
as in the cerebrospinal fluid [50]. The redundancy of glucose
transporters in neurons should be able to prevent or reduce the
possibility of neurotoxic effect using WZB117. When used in
the animal model, no neurotoxicity was reported for WZB117
treatment [33]. To inhibit mitochondrial metabolism, the best
candidate at the moment is metformin. Metformin is a widely
used drug in the treatment of T2D, with a good toxicity and
safety profile, and is an efficient inhibitor of the electron trans-
port chain. However, metformin has a wide range ofmetabolic
effects, making it more difficult to predict potential interac-
tions or side effects when used in combination with other
metabolic inhibitors. To block glutaminolysis, the best candi-
date at the moment is the glutaminase inhibitor CB839. Even
though the results of the use of CB839 in clinical trials have
not been reported yet, inhibition of glutaminase with DON
and BPTES showed important side effects and toxicity [51].
Therefore, we expect the use of CB839 to be the most prob-
lematic in a metabolic inhibition strategy. An important aspect
to be considered in the metabolic inhibition approach is the
potential synergies of metabolic inhibitors. Metabolic path-
ways are highly redundant and the availability of oxygen,
and nutrients can rapidly induce a shift in cell metabolism.
The simultaneous blocking of the three main metabolic path-
ways can potentially induce anergy and apoptosis in activated
Tcells at concentrations far lower than that of the single drugs.
With the current knowledge and the therapeutic arsenal of
metabolic inhibitors available, we think that a triple metabolic
inhibition strategy with WZB117, metformin, and CB839,
administered for a 2-week period after antigen-specific activa-
tion of autoreactive T cells, is the strategy that conjugates a
selective and durable effect on the autoreactive T-cell pool,
limiting potential toxicity and side effects. The discovery of
novel metabolic inhibitors and their testing in clinical trials
could result in important improvements of this strategy in
the near future [52].
Conclusions
Metabolic inhibition as a strategy to control the T-cell re-
sponse is gaining increasing interest in most of the diseases
involving T cells, including transplantation, cancer, and auto-
immunity. Immunotherapy for T1D is currently limited by the
Figure 2 A model for T-cell metabolic blockade. The strategy for
metabolic blockade after T-cell activation consists of the inhibition of
the glycolytic pathway early after activation and later of the
mitochondrial metabolism for 2 weeks in order to induce apoptosis and
unresponsiveness selectively in antigen activated T cells. oxphos
oxidative phosphorylation
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relative toxicity and side effects of metabolic inhibitors.
However, this is a rapidly expanding field of research in phar-
macology, and novel drugs may soon be available to design a
treatment with a better safety profile. We believe that we are
now in the position to start considering this approach, improve
our knowledge about the metabolic changes during activation
of autoreactive T cells, and set up preclinical models to deter-
mine if this strategy is effective for a future translation in
clinical immunotherapy.
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